CDC Group has invested in a $300 million fund from Adjuvant Capital focused on accelerating the development of medical innovations for historically overlooked public health challenges. Launched in 2019, Adjuvant’s debut fund will support promising new technologies that the venture capital industry has largely ignored.

“Billions of people around the world live under constant assault from diseases like malaria, shigella, hookworm, tuberculosis, and Lassa fever, yet Wall Street and Si...